Anti-Hypertensive Drugs - Haiti

Haiti

Highlights

The projected revenue for the Anti-Hypertensive Drugs market in Haiti is expected to reach US$2.29m in 2024.
It is anticipated that the market will experience an annual growth rate of -0.38% between 2024 and 2029, leading to a market volume of US$2.24m by 2029.
In terms of global comparison, United States is estimated to generate the highest revenue in this market, amounting to US$12.29bn in 2024.
In Haiti, the demand for affordable and accessible anti-hypertensive drugs is on the rise due to the high prevalence of hypertension in the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Haiti has been showing interesting developments in recent years.

Customer preferences: Haiti has a high prevalence of hypertension, which has led to an increasing demand for Anti-Hypertensive Drugs. The majority of Haitians rely on public healthcare, and therefore, affordability is a significant factor in their drug choices. Patients are more likely to opt for generic drugs due to their lower prices, and availability in local pharmacies is also a crucial factor in their purchasing decisions.

Trends in the market: The Anti-Hypertensive Drugs market in Haiti has been growing due to an increase in the prevalence of hypertension. The market has been dominated by ACE inhibitors, calcium channel blockers, and diuretics. However, there has been a recent trend towards the use of combination therapy, which has led to an increase in the sales of fixed-dose combination drugs. Additionally, there has been an increase in the availability of generic drugs, which has led to a shift in consumer preferences towards these lower-cost options.

Local special circumstances: The healthcare system in Haiti faces several challenges, including limited resources, inadequate infrastructure, and a shortage of healthcare professionals. These challenges have led to a lack of access to healthcare services and drugs in some areas. Additionally, the country has faced political instability, natural disasters, and economic challenges, which have further strained the healthcare system and limited access to drugs.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the Western Hemisphere, with a low GDP per capita and a high poverty rate. The country relies heavily on foreign aid, and the healthcare system is underfunded, leading to limited access to drugs and healthcare services. The country has also faced political instability, natural disasters, and economic challenges, which have further strained the healthcare system and limited access to drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.